Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/145252
Full metadata record
DC FieldValueLanguage
dc.creatorVieira, FQ
dc.creatorMarques-Magalhães, Â
dc.creatorMiranda-Gonçalves, V
dc.creatorFerraz, R
dc.creatorVieira, M
dc.creatorPrudêncio, C
dc.creatorJerónimo, C
dc.creatorSilva, RA
dc.date.accessioned2022-11-17T11:32:59Z-
dc.date.available2022-11-17T11:32:59Z-
dc.date.issued2020
dc.identifier.issn1661-6596
dc.identifier.urihttps://hdl.handle.net/10216/145252-
dc.description.abstractBreast (BrCa) and prostate (PCa) cancers are the most common malignancies in women and men, respectively. The available therapeutic options for these tumors are still not curative and have severe side effects. Therefore, there is an urgent need for more effective antineoplastic agents. Herein, BrCa, PCa, and benign cell lines were treated with two ionic liquids and two quinoxalines and functional experiments were performed—namely cell viability, apoptosis, cytotoxicity, and colony formation assays. At the molecular level, an array of gene expressions encompassing several molecular pathways were used to explore the impact of treatment on gene expression. Although both quinoxalines and the ionic liquid [C2OHMIM][Amp] did not show any effect on the BrCa and PCa cell lines, [C16Pyr][Amp] significantly decreased cell viability and colony formation ability, while it increased the apoptosis levels of all cell lines. Importantly, [C16Pyr][Amp] was found to be more selective for cancer cells and less toxic than cisplatin. At the molecular level, this ionic liquid was also associated with reduced expression levels of CPT2, LDHA, MCM2, and SKP2, in both BrCa and PCa cell lines. Hence, [C16Pyr][Amp] was shown to be a promising anticancer therapeutic agent for BrCa and PCa cell lines.
dc.description.sponsorshipThis research was funded by NORTE-01-0145-FEDER-024156, co-funded by Programa Operacional Regional do Norte (NORTE 2020) through Portugal 2020 and Fundo Europeu de Investimento Regional (FEDER), and by Fundação para a Ciência e a Tecnologia (FCT).
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofInternational Journal of Molecular Sciences, vol.21(24):9584
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBreast cancer
dc.subjectIonic liquids
dc.subjectProstate cancer
dc.subjectQuinoxalines
dc.subjectTreatment
dc.subject.meshAmpicillin / chemistry
dc.subject.meshAntineoplastic Agents / chemistry
dc.subject.meshAntineoplastic Agents / pharmacology
dc.subject.meshApoptosis / drug effects
dc.subject.meshBreast Neoplasms / metabolism
dc.subject.meshCell Line, Tumor
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshIonic Liquids / chemistry
dc.subject.meshIonic Liquids / pharmacology
dc.subject.meshMale
dc.subject.meshProstatic Neoplasms / metabolism
dc.subject.meshPyridinium Compounds / chemistry
dc.subject.meshQuinoxalines / chemistry
dc.titleThe impact of [c16pyr][amp] on the aggressiveness in breast and prostate cancer cell lines
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/ijms21249584
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/21/24/9584
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-ijms21249584.pdf1.65 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons